We are live on ! Find out more
PDSB icon

PDS Biotechnology

0.3070 USD
+0.0070
2.33%
At close Updated Sep 9, 10:04 AM EDT
1 day
2.33%
5 days
52.74%
1 month
-58.01%
3 months
-70.19%
6 months
-55.19%
Year to date
-63.15%
1 year
-73.98%
5 years
-98.04%
10 years
-99.85%
 

About: PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

Employees: 21

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 25%
Neutral 50%
Negative 25%
Neutral
GlobeNewsWire
1 day ago
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
Dr. Soon-Shiong will Join PDS Biotech's Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity (“PIPE”) transaction.
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
Neutral
GlobeNewsWire
27 days ago
PDS Biotech Reports Second Quarter 2026 Financial Results
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today provided a business and clinical programs update and reported financial results for the quarter ended June 30, 2026.
PDS Biotech Reports Second Quarter 2026 Financial Results
Negative
Benzinga
28 days ago
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
Positive
Zacks Investment Research
3 months ago
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
Neutral
MarketBeat
3 months ago
PDS Biotechnology Q1 Earnings Call Highlights
PDS Biotechnology NASDAQ: PDSB reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs.
PDS Biotechnology Q1 Earnings Call Highlights
Neutral
Seeking Alpha
3 months ago
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Neutral
GlobeNewsWire
4 months ago
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and will provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am Eastern Time.
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
Neutral
GlobeNewsWire
4 months ago
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35%
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
Neutral
Seeking Alpha
5 months ago
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
Price charts implemented using Lightweight Charts™